New drug HLX43 aims to shrink Hard-to-Treat gynecologic cancers

NCT ID NCT06769152

Recruiting now Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tumors and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLX43 (a drug that combines an antibody targeting PD-L1 with a chemotherapy-like toxin)
What this could lead to: If successful, this could offer a new treatment option for people with advanced cervical or ovarian cancer who have run out of standard options.
What could go wrong: This is an early Phase 2 trial with only 190 participants, so results may not apply to everyone. The drug may cause side effects or not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer fallopian tube cancer fallopian tube serous adenocarcinoma ovarian cancer ovarian serous adenocarcinoma primary peritoneal carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER OVARIAN CANCER

Contacts and locations

Locations

Shandong Cancer Hospital
RECRUITING

Ji'nan, Shandong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.